Science 37 Holdings Equity 2024

Science 37 Holdings Aktienanalyse

What does Science 37 Holdings do?

Science 37 Holdings Inc. is a company specializing in clinical trials supported by technology and digital methods. It was founded in 2014 by a team of experienced medical and technological experts. The company is headquartered in Los Angeles, California, USA. Science 37's business model focuses on accelerating clinical trials and reducing costs by facilitating access to patients and data through a digital, telemedicine-based infrastructure. This is changing the way clinical trials are conducted by addressing one of the biggest obstacles to industrial development: the lengthy recruitment of patients. The various divisions of Science 37 include a platform for telemedicine studies, which allows virtual researchers to assess and connect with patients remotely, an in-house platform for clinical data management and analysis, and an extensive network of physicians and patients who offer and participate in clinical studies. Science 37's partners include pharmaceutical companies, biotech companies, academic institutions, and government agencies. Science 37 offers a wide range of products tailored to the specific needs of its customers. These products include: 1. NORA - A telemedicine platform for near-site recruitment, which allows patients to conveniently participate in a clinical trial through their own device. The platform provides a seamless and integrated experience for the patient and facilitates collaboration between study centers and virtual researchers. 2. NEST - A platform for clinical studies designed for the management of large data-driven studies. NEST provides a central database that simplifies the collection and management of study data and complies with compliance requirements. 3. SIV - A cloud-based platform for site initiation visits, which allows sponsors to accelerate study initiation with a wealth of site information without the need for an on-site visit. 4. Decentralized Clinical Trials - A fully digital platform that supports a clinical study from recruitment to data analysis and uses the "bring your own device" paradigm (BYOD). Decentralized Clinical Trials allow access from anywhere, whenever the patient desires. The company has an impressive track record, having worked on more than 27 clinical trials and being awarded numerous accolades, including "Most Innovative Clinical Trial Solution Provider" at the Global Health & Pharma (GHP) Awards 2019. Overall, Science 37 is an innovative company that has revolutionized the way clinical trials are conducted. Technology has the potential to radically transform medical research and accelerate drug development. Science 37 is pushing the boundaries of what is possible in large-scale patient recruitment and is a key player in the digital transformation of clinical research. Science 37 Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Science 37 Holdings's Equity

Science 37 Holdings's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Science 37 Holdings's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Science 37 Holdings's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Science 37 Holdings's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Science 37 Holdings’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Science 37 Holdings stock

What is the equity of Science 37 Holdings this year?

Science 37 Holdings has equity of 97.4 M USD this year.

What was the equity of Science 37 Holdings compared to the previous year?

The equity of Science 37 Holdings has increased/decreased by -19.9% decreased compared to the previous year.

What impact does a high equity have on investors of Science 37 Holdings?

A high equity is advantageous for investors of Science 37 Holdings as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Science 37 Holdings?

A low equity can be a risk for investors of Science 37 Holdings, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Science 37 Holdings affect the company?

An increase in equity of Science 37 Holdings can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Science 37 Holdings affect the company?

A reduction in equity of Science 37 Holdings can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Science 37 Holdings?

Some factors that can affect the equity of Science 37 Holdings include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Science 37 Holdings so important for investors?

The equity of Science 37 Holdings is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Science 37 Holdings take to change the equity?

To change equity, Science 37 Holdings can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Science 37 Holdings pay?

Over the past 12 months, Science 37 Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Science 37 Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Science 37 Holdings?

The current dividend yield of Science 37 Holdings is .

When does Science 37 Holdings pay dividends?

Science 37 Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Science 37 Holdings?

Science 37 Holdings paid dividends every year for the past 0 years.

What is the dividend of Science 37 Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Science 37 Holdings located?

Science 37 Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Science 37 Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Science 37 Holdings from 9/14/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/14/2024.

When did Science 37 Holdings pay the last dividend?

The last dividend was paid out on 9/14/2024.

What was the dividend of Science 37 Holdings in the year 2023?

In the year 2023, Science 37 Holdings distributed 0 USD as dividends.

In which currency does Science 37 Holdings pay out the dividend?

The dividends of Science 37 Holdings are distributed in USD.